Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Releases New CytoSure™ ISCA +SNP Array

Published: Monday, September 24, 2012
Last Updated: Monday, September 24, 2012
Bookmark and Share
New microarray for accurate detection of copy number changes and loss of heterozygosity using a single array.

Oxford Gene Technology (OGT) has released the latest addition to its range of CytoSure™ ISCA microarrays for reliable and standardized genomic aberration detection.

The new patent pending CytoSure ISCA +SNP (4x180k) array combines array comparative genomic hybridization (aCGH) probes, endorsed by the International Standards for Cytogenomic Arrays (ISCA) Consortium, with fully validated single nucleotide polymorphism (SNP) content.

This allows the accurate and cost-effective detection of copy number changes and loss of heterozygosity (LOH) using a single array.

As the newest member of the CytoSure ISCA array portfolio, the CytoSure™ ISCA +SNP array includes enhanced SNP coverage for high-resolution LOH detection.

This means that the analysis of genetically complex samples from related individuals is now even more accurate and in-depth, while integration with OGT’s powerful and intuitive CytoSure Interpret Software ensures that analysis is easy, fast and insightful.

James Clough, Vice President Clinical and Genomic Solutions at OGT, commented: “For several years, OGT has worked closely with ISCA to design a range of arrays focused on providing standardized, evidence-based content. The latest CytoSure ISCA +SNP design is part of our ongoing commitment to further enhancing the accuracy, reproducibility and efficiency of genomic analysis using microarrays, by creating powerful, multi-feature arrays that generate as much relevant data as possible.”

Although aCGH is the gold standard for detecting copy number variation (CNV), until recently it was not possible to combine this technique with LOH and uniparental disomy (UPD) detection using SNP probes.

This meant that either two separate arrays were needed, or that inferior SNP-based CNV detection platforms were used. To solve this problem, the CytoSure ISCA +SNP array allows CNV and SNP detection to be carried out on a single array, using optimized probes that are fit for each purpose.

By allowing both methods to work efficiently under standard CytoSure aCGH hybridization conditions, these arrays fit seamlessly into existing workflows.

To provide as much relevant information as possible, the arrays include content specifically designed to focus on disease and syndrome-associated regions, in addition to offering whole genome ‘backbone’ coverage.

To simplify the analysis of samples such as those suspected of exhibiting UPD, OGT provides all users of CytoSure arrays with its industry-leading CytoSure Interpret Software.

With various innovative features, the software maximizes the ease, consistency and speed of data interpretation, while minimizing the need for user intervention.

The results provided include extensive annotation tracks covering syndromes, genes, exons, CNVs and recombination hotspots, while links to publicly available databases put results into context.

Using the comprehensive range of CytoSure products, the transition from sample to biological insight is always fast, accurate and reliable.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Friday, July 17, 2015
OGT Signs License with Wellcome Trust Sanger Institute
OGT will use novel data on developmental disorders to advance microarray and NGS products for accurate and cost effective identification of rare diseases.
Saturday, April 04, 2015
Oxford Gene Technology Awarded £1.2m Genomics England Contract
Next Generation Sequencing analysis software will support 100,000 Genomes Project by providing intuitive reports for clinical interpretation.
Monday, March 16, 2015
OGT Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m.
Tuesday, December 09, 2014
Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
OGT workshop provides insight on using complementary genomic technologies.
Friday, November 07, 2014
An Integrated Approach to Clinical Genetics Research
OGT’s new whitepaper explores the next stage of molecular testing.
Wednesday, April 09, 2014
OGT Announces Acquisition of Cytocell Ltd
Company expands leadership in genomic medicine.
Thursday, March 06, 2014
Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
New Whitepaper Compares Targeted Resequencing Strategies
OGT provides insight into choice of NGS methods.
Wednesday, July 17, 2013
OGT Initiates Strategic Expansion Plans in North America
Opening of New York office and appointment of US sales team.
Tuesday, November 20, 2012
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!